Alzinova AB (OSTO:ALZ) OCF Margin %: 0.00% (As of Mar. 2026)


OSTO:ALZ Alzinova AB OSTO:ALZ
21 GF Score
Price kr0.55
! 1 Warning Sign
View Full Analysis

What is Alzinova AB OCF Margin %?

Alzinova AB OSTO:ALZ +0.55% 21 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:ALZ with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 958 Biotechnology companies, Alzinova AB ranks worse than 104384.03% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Alzinova AB's Cash Flow from Operations for the three months ended in Mar. 2026 was kr-16.80 Mil. Alzinova AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Alzinova AB's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Alzinova AB's current OCF Yield % is -21.66%.

The historical rank and industry rank for Alzinova AB's OCF Margin % or its related term are showing as below:


OSTO:ALZ's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Alzinova AB OCF Margin % Related Terms

Alzinova AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Alzinova AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzinova AB OCF Margin % Chart

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alzinova AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ALZ
21GF Score
Alzinova AB OSTO:ALZ
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzinova AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Alzinova AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-13.03/0
= %

Alzinova AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.801/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Alzinova AB (OSTO:ALZ) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alzinova AB and its competitors. According to the industry distribution chart, Alzinova AB ranks #999999 out of 958 companies in the Biotechnology industry.
Is Alzinova AB's OCF Margin % too high?
Alzinova AB's current OCF Margin % is 0.00%. Based on the distribution chart, Alzinova AB ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzinova AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzinova AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzinova AB ranks #999999 out of 958 companies for OCF Margin %. This places Alzinova AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alzinova AB and its competitors. Alzinova AB's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzinova AB stock overvalued right now?
Alzinova AB (OSTO:ALZ) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Alzinova AB's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Alzinova AB (OSTO:ALZ), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzinova AB Business Description

Other Exchanges 78D:Germany
Address Entreprenorsstraket 10, Molndal, SWE, 431 53
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
21GF Score

Get the complete analysis for OSTO:ALZ

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.55
Price